Purpose: Radiotherapy is integral in the management of hematological malignancies (HM). Standard radiotherapy dose fractionation regimens range between 20 and 50 Gy in 10-25 fractions over 2-5 weeks. This study presents the outcomes of patients with HM treated with hypofractionation radiotherapy (HFRT) during the COVID-19 pandemic.
Methods: Patients (n = 36) were treated with HFRT between January 2020 and September 2022. The outcomes measured were the overall response rate (ORR), freedom from local progression (FFLP), and overall survival (OS).
Results: The median follow-up was 13.2 months. Thirty-three patients (92%) had non-Hodgkin (NHL) or Hodgkin lymphoma (HL). Eighteen patients (50%) had aggressive and nine (25%) had indolent NHL. Nineteen patients (53%) presented with stage I/II and fifteen (42%) with stage III/IV disease. Twenty-five (69.4%) and eleven (30%) received consolidative and definitive RT, respectively. Twenty patients (56%) received treatment to the neck and/or thorax and nine (25%) to the abdomen or pelvis. The total dose ranged from 18 to 42.5 Gy in 6-17 fractions/2.67-5 Gy per fraction. The median dose in 2 Gy fractions for an alpha/beta (α/β) ratio of 10 amounted to 39 Gy (SD ± 13.86) and 43.6 Gy (SD ± 12) for an α/β of 3. The most commonly used fractionation scheme was 39 Gy in 13 fractions. ORR was 94.4% for the entire cohort, and 100, 94.4, and 83.3% for indolent NHL, aggressive NHL, and HL patients. The two-year FFLP was 76% (95% CI: 34-93%) for the entire cohort and 100, 87 (95% CI: 56.4-96.5%), and 42% (95% CI: 1.1-84.3%) for the indolent NHL, aggressive NHL, and HL patients. Two-year OS for the entire cohort was 80% (95% CI: 59.9-90.5%) and 100, 66.1 (95% CI: 36.4-84.4%), and 100% for the indolent NHL, aggressive NHL, and HL patients. Only one patient presented with grade two pulmonary toxicity.
Conclusions: HFRT in HM provides excellent local control to be validated in a larger prospective study.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10814841 | PMC |
| http://dx.doi.org/10.3390/curroncol31010025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ESR Essentials: imaging of lymphoma-practice recommendations by the European Society of Oncologic Imaging.
Eur Radiol
January 2025
Department of Radiology, NYU Grossman School of Medicine, New York, USA.
Imaging is used for lymphoma detection, Ann Arbor/Lugano staging, and treatment response assessment. [F]FDG PET/CT should be used for most lymphomas, including Hodgkin lymphoma, aggressive/high-grade Non-Hodgkin lymphomas (NHL) such as diffuse large B-cell lymphoma, and many indolent/low-grade NHLs such as follicular lymphoma. Apart from these routinely FDG-avid lymphomas, some indolent NHLs, such as marginal zone lymphoma, are variably FDG-avid; here, [F]FDG PET/CT is an alternative to contrast-enhanced CT at baseline and may be used for treatment response assessment if the lymphoma was FDG-avid at baseline.
View Article and Find Full Text PDFNodular lymphocyte-predominant Hodgkin lymphoma revisited: current management strategies and future perspectives.
Leuk Lymphoma
January 2025
First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany.
Article Synopsis
- Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare type of lymphoma, making up about 5% of Hodgkin lymphoma cases, and shares some characteristics with B-cell non-Hodgkin lymphoma.
- NLPHL is typically diagnosed at early stages and has a slow progression, leading to excellent long-term survival rates for most patients.
- Treatment mainly mirrors classical Hodgkin lymphoma but may include rituximab; future strategies could involve innovative therapies like CAR T-cell therapy and bispecific antibodies.
Challenging granulomatous differential diagnosis of CNS lesions in a 75-year-old patient with indolent lymphoma.
Front Immunol
December 2024
Department of Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany.
We report here on a patient with concomitant indolent lymphoma who showed a rapid progressive deterioration of his general condition and emerging neurological symptoms. The combination of severe B symptoms with hypermetabolic involvement of the adrenal glands and multiple central nervous system (CNS) lesions initially suggested a malignant disease. However, when the patient presented to us with biopsy results from one of the CNS lesions, the biopsy revealed granulomatous inflammation but no evidence of malignancy.
View Article and Find Full Text PDFFollicular Lymphoma Presenting as a Primary Omental Mass: A Case Report and Pathological Analysis.
Cureus
November 2024
Department of Radiology, Sri Ramaswamy Memorial (SRM) Medical College Hospital and Research Center, Sri Ramaswamy Memorial Institute of Science and Technology (SRMIST), Chengalpattu, IND.
Follicular lymphoma (FL) is a gradually progressing type of B-cell non-Hodgkin lymphoma (NHL), distinguished by its characteristic follicular pattern of growth and a typically indolent clinical course. It is identified by the abnormal growth of B-cells in the lymph nodes. We report a case of a 45-year-old female who came up with complaints of heavy menstrual bleeding and easy fatiguability.
View Article and Find Full Text PDFEvaluating plasma antinuclear autoantibody profile as a prognostic biomarker in lymphoma.
BMC Cancer
November 2024
Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK and PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Background: Research on the antinuclear antibodies (ANA) profile across different pathological subtypes of lymphoma was limited. Our study aimed to assess ANA profile and investigate its potential prognostic value in lymphoma.
Method: We collected plasma samples from 139 lymphoma patients and analyzed the expression of plasma ANA, SSA, and SSB using the enzyme-linked immunosorbent assay (ELISA).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!